Tell Gilead 44% Effectiveness is Not Enough:
Please join AIDS Healthcare Foundation in expressing concern about PrEP, an ineffective use of Gilead’s treatment Truvada for HIV prevention.
An effectiveness rate of 44% is just not enough to warrant FDA approval.
Send the e-letter below to the Chairman and CEO of Gilead Sciences, Inc. John C. Martin.
Gilead, There is No Magic Pill
Dear Mr. John C. Martin,
I am concerned about possible approval by the U.S. Food & Drug Administration (FDA) of Gilead Sciences, Inc.'s drug Truvada as a pre-exposure prophylaxis (PrEP) to prevent HIV transmission. The results of a recent study using Truvada as PrEP, involving 2,500 gay men and showing a 44% effectiveness rate in preventing HIV are insufficient to support FDA approval of Truvada as an HIV prevention tool for gay men for numerous reasons. First and foremost, a rate of 44% preventive effectiveness is much too low to merit FDA approval. Secondly, at this time, real-world information is lacking. I am deeply concerned about the possibility of increased risk that could come with the use of Truvada as PrEP. The consequences of patients who take Truvada haphazardly are that they will become infected, develop drug resistance, and spread drug-resistant virus to others. There is also the very real potential that there will be a decrease in condom usage due to a false sense of protection from taking PrEP. Finally, there is the question of who will pay for this $35-a-day pill. Currently, there are more than 6,450 low-income Americans who are living with HIV/AIDS who are on waiting lists to receive lifesaving medications from state AIDS programs because funding is shrinking. I join AIDS Healthcare Foundation in supporting continued research on HIV prevention, but opposing quick fixes that run the risk of contributing to the spread of HIV and drug-resistant viruses. Please halt any further pursuit of FDA approval for Truvada as PrEP until further study is completed.
Sincerely,[Your Name] [Your Address] [City, State ZIP]